The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].
 
Dejka M. Araujo
Research Funding - Adaptimmune (Inst); GlaxoSmithKline (Inst); Immatics (Inst)
 
Brian H. Ladle
No Relationships to Disclose
 
Kai He
Consulting or Advisory Role - Bristol-Myers Squibb; Geneplus; Iovance Biotherapeutics; Mirati Therapeutics; Perthera
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst)
 
Benjamin Powers
No Relationships to Disclose
 
Amanda McGillivray
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Ionel Mitrica
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Wenlei Liu
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Nitin Patel
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Sandra P. D'Angelo
Honoraria - Adaptimmune; GlaxoSmithKline; Pfizer; Rain Therapeutics; SERVIER
Consulting or Advisory Role - Adaptimmune; GlaxoSmithKline; Nektar; Pfizer; Rain Therapeutics; Rain Therapeutics; Servier